New Delhi: The Drug Administration General of India (DGCI) has approved emergency use for Zydus Cadila’s pegylated Interferon alfa-2b, ‘Virafin’ for the treatment of moderate COVID-19 infection in adults.
A release by Cadila Health states: “The drug also shows effectiveness against other viral infections.”
Dr Sharvil Patel, managing director of Cadila Healthcare Limited, said of the development: “The fact that we can offer a therapy that significantly reduces the viral load if we are administered early can help manage diseases. It comes on ‘ a much-needed time for patients and we will continue to give them access to critical therapies in this fight against COVID-19. ”
This government’s approval for the use of the antiviral drug comes at a time when India is doing it daily COVID exceeds the 3-lakh mark.
India recorded 3,32,730 new COVID-19 cases in the past 24 hours, the highest one-day rise since the pandemic broke out last year. India exceeds 3 lakh mark COVID-19 matters now for two consecutive days.
It has the cumulative score of the COVID infection in the country to 1,62,63,695.
Source: Telangana Today